Tags:DevelopmentEngineeringGrowthManufacturingPublicResearch
Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The company’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair. Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with sotatercept in pulmonary arterial hypertension.
Location: United States, Massachusetts, Cambridge
Total raised: $30M

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
23.12.2011-$30M--

Mentions in press and media 13

DateTitleDescriptionCategoryAuthorSource
01.10.2021Why the au...This is the web version of Ter...--fortune.co...
30.09.2021Merck to b...Merck & Co. agreed to buy ...--business-s...
18.06.2021ACCELERON ...Reblozyl was generally well to...--marketscre...
29.03.2019bluebird’s...Shares of bluebird on the Nasd...--medcitynew...
20.03.2019Flagship P...“With each year of company ori...--medcitynew...
03.01.2018A bet­ter ...Schol­ar Rock, a biotech based...FinancingBrittany M...endpts.com...
26.03.2015Flagship V...The company’s previous fund wa...--medcitynew...
01.11.2013OrbiMed cl...Looking back 5 to 6 years, hea...--medcitynew...
30.10.2013Which vent...I won’t get into Aratana Thera...--medcitynew...
20.01.2012Boston’s T...Share Share on Facebook Share ...-Gregory T....xconomy.co...
Show more